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Colorectal cancer (CRC) develops as multistep process, which involves genetic and epigenetic alterations. K-Ras, p53 and B-Raf
mutations and RASSF1A, E-Cadherin and p16INK4A promoter methylation were investigated in 202 CRCs with and without lymph
node and/or liver metastasis, to assess whether gene abnormalities are related to a metastogenic phenotype. K-Ras, B-Raf and p53
mutations were detected in 27, 3 and 32% of the cases, with K-Ras mutations significantly associated with metastatic tumour
(P¼0.019). RASSF1A, E-Cadherin and p16INK4A methylation was documented in 20, 44 and 33% of the cases with p16INK4A
significantly associated with metastatic tumours (P¼0.001). Overall, out of 202 tumours, 34 (17%) did not show any molecular
change, 125 (62%) had one or two and 43 (21%) three or more. Primary but yet metastatic CRCs were prevalent in the latter group
(P¼0.023) where the most frequent combination was one genetic (K-Ras in particular) and two epigenetic alterations. In conclusion,
this analysis provided to detect some molecular differences between primary metastatic and nonmetastatic CRCs, with K-Ras and
p16INK4A statistically altered in metastatic tumours; particular gene combinations, such as coincidental K-Ras mutation with two
methylated genes are associated to a metastogenic phenotype.
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Colorectal cancer (CRC) is one of the most common malignant
neoplasm worldwide. The prognosis is significantly affected by the
tumour stage that mainly rests on the ability to metastasise to
lymph nodes and/or to the liver. Indeed, the 5-year-survival is over
90% for Duke’s stage A, but only 5% for Duke’s stage D
(de la Chapelle, 2004). Sequential and additional genetic alterations
affecting several proto-oncogenes and tumour suppressor genes
have been recognised in the pathogenesis of CRC. Less known
are the molecular events responsible for the progression and
metastatisation of CRC; it is reasonable that the molecular
profile of primary but yet metastatic CRC may be helpful to
understand the molecular basis of extracolic tumour spread and to
define therapeutic strategies against ‘metastogenic’ genes. Previous
studies targeted to ascertain the molecular progression of CRC
investigated genetic abnormalities of proto-oncogenes (K-Ras) and
tumour suppressor genes (p53 and APC) or, alternatively,
molecular epigenetic changes (E-Cadherin, p16INK4A, DAPK,
RASSF1A and APC) (Smith et al, 2002; Lee et al, 2004). The
present study was aimed to investigate both genetic and epigenetic
changes occurring in CRC by comparing the molecular profiles of
primary metastatic and nonmetastatic tumours. We selected for
study the mutational status of K-Ras, B-Raf and p53 and the
epigenetic status of RASSF1A, E-Cadherin and p16INK4A.
Abnormalities of K-Ras are key events in colorectal carcino-
genesis and mutations of the gene arise early during the colonic
transformation in 20–50% of the tumours (Bazan et al, 2002).
K-Ras has been also implicated in the process of tumour invasion
and metastasis (Giehl, 2005). Mutations that prevalently occur at
codon 12, prevent efficient GTP-hydrolysis and thus render the
protein in an activated state. As a result, multiple Ras effector
pathways, which control fundamental biological processes such as
proliferation, apoptosis and cell motility become constitutively
activated and/or deregulated (Pollock et al, 2005). The best
characterised Ras effectors are the Raf serine/threonine kinases
(A-Raf, B-Raf and Raf-1) that upregulate the MAP kinase cascade
(Kolch, 2000). Davies et al (2002) recently reported that B-Raf
mutations play a pivotal role in the oncogenesis of melanoma and
colorectal carcinoma. The majority of analysed samples exhibited
one specific B-Raf alteration that caused the exchange of valine to
glutamate, a negatively charged amino acid, at position 599
(V599E) in the kinase domain of the protein. Interestingly, it has
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sbeen shown that this alteration causes the growth of carcinoma cell
lines independent from Ras activation.
The p53 suppressor gene encodes a nuclear phosphoprotein that
regulates cell cycle and apoptosis. Mutations in this gene constitute
some of the most frequently occurring genetic changes at human
malignancies and are thought to be late development in the
adenoma–carcinoma sequence in CRC (Fearon and Vogelstein,
1990). Mutations in this gene increase the protein half-life and are
often associated with protein overexpression in the nucleus
(Remvikos et al, 1990). Mutations most commonly occur in the
highly conserved region (exons 5–8), which encodes the DNA-
binding domain (Zhang et al, 1997).
During the last decade, epigenetic changes have been reported
in many cancers and they are now recognised to be at least as
common as genetic changes. Hypermethylation of selected CpG
sites within CpG islands in the promoter region of tumour
suppressor genes is associated with loss of gene expression and is
observed in both physiological conditions and neoplasia (Kim
et al, 2005b). By inactivating various tumour suppressor genes,
this epigenetic modification can affect many important cellular
processes, such as cell proliferation, apoptosis, invasion and
metastasis.
RASSF1 proteins are potential Ras effectors and the major
isoform, RASSF1A, is an important human tumour suppressor
protein acting at G1/S phase of cell-cycle progression (Dammann
et al, 2003). This protein can induce cycle arrest by cyclin D1
inhibition. The RASSF1A locus at 3p21.3 is methylated at high
frequency in a variety of solid tumours including CRC, where this
gene has been analysed as an alternative marker to downregulate
Ras pathway (Pizzi et al, 2005).
E-Cadherin belongs to a family of Ca
2þ-dependent adhesion
molecules that mediate intercellular contacts critical to morpho-
genesis and the maintenance of tissue structure (Takeichi, 1995).
Reduced expression of E-Cadherin owing to aberrant CpG island
hypermethylation has been regarded as one of the main molecular
events involved in the dysfunction of the cell–cell adhesion system
(Darwanto et al, 2003), in invasion and metastasis (Garinis et al,
2002). Recently, it has been shown that loss of E-Cadherin
expression in a transgenic mouse model is associated with the
development of invasive colorectal carcinoma from well-differ-
entiated adenomas (Wheeler et al, 2001).
p16INK4A gene is one of the most frequently inactivated tumour
suppressor genes in human cancer (Kamb et al, 1994). The
p16INK4A product, an inhibitor of cyclin-dependent kinases 4 and
6, is capable of preventing Rb phosphorylation, thus blocking cells
in the G1 phase of the cell cycle (Serrano et al, 1996). It is known
that p16INK4A expression in colon cancer cells is repressed by
methylation at the CpG island of promoter, but in vivo silencing of
p16INK4A methylation has not been widely investigated (Kim et al,
2005a).
We designed a study aimed to compare genetic and epigenetic
changes occurring in primary advanced nonmetastatic CRCs as
opposed to primary advanced metastatic CRCs. The target was to
establish in CRCs if and which genetic and epigenetic molecular
abnormalities, among a number of selected genes, are associated to
a metastogenic phenotype.
MATERIALS AND METHODS
Patients
This study includes 202 consecutive primary advanced metastatic
and nonmetastatic CRCs surgically removed from 1997 to 2002.
Table 1 reports the main clinico-pathological features of the series.
We elected to study and to compare two homogeneous groups of
CRC cases, namely those invading through muscolaris mucosa into
subsierosa (or into nonperitonealised pericolic or perirectal tissues)
with and without lymph nodes and/or liver metastases. In such a
way, the only significant morphological and biological variable
between the two groups was the presence of metastatic deposits.
Accordingly, these two groups will be referred to throughout the
paper as metastatic (Mþ) and nonmetastatic (M ) tumours.
DNA extraction
Samples were fixed in formalin and embedded in paraffin. Paraffin
blocks were cut into several 2mm sections. One section from each
tissue was stained with hematoxylin–eosin to distinguish neo-
plastic tissue from the nonmalignant counterpart. After manual
dissection, DNA was extracted from the unstained section of the
malignant tissue as described previously (Roncalli et al, 2002).
Briefly, tissue sections were deparaffinised using 100% xylene
(Sigma, Saint Louis, MO, USA) followed by 100% ethanol. The
pellet was then resuspended in a buffer containing proteinase K
(Finnzyme, Espoo, Finland), and DNA was extracted with phenol–
chloroform (Sigma, Saint Louis, MO, USA) followed by ethanol
precipitation. Finally, precipitated DNA was resuspended in 100ml
of water. DNA was quantified spectrophotometrically, and 200ng
were used as a template for each PCR amplification.
Table 1 Clinico-pathological features of the series under study as related to M+ and M  tumours
All patients M  M+
n¼202 (100%) n¼72 (100%) n¼130 (100%) Univariate analysis
Age (years7s.d.) 66.05711.66 69.40711.44 64.2711.40 P¼0.002
Sex
F 81 (40%) 26 (36%) 55 (42%) NS
M 121 (60%) 46 (64%) 75 (58%)
Location
R 71 (35%) 23 (32%) 48 (37%) NS
L 78 (39%) 30 (42%) 48 (37%)
Re 53 (26%) 19 (26%) 34 (26%)
Grading
G1 14 (7%) 9 (13%) 5 (4%) P¼0.069
G2 145 (72%) 47 (65%) 98 (75%)
G3 43 (21%) 16 (22%) 27 (21%)
F¼female; L¼left side; M¼male; M+¼metastatic tumours; M ¼nonmetastatic tumours; NS¼not significant; R¼right side; Re¼rectum; s.d.¼standard deviation.
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Mutations at codon 12 of the K-Ras gene and at codon 599 of the
B-Raf gene were detected by PCR–RFLP that identifies codon 12
and 599 mutations but not the specifically altered nucleotide.
K-Ras codon 12 mutations were detected using the BstNI
restriction enzymes (New England Biolabs Inc., Beverly, MA,
USA). Briefly, 200ng of DNA were used as template for the first
PCR, which consisted of a 50ml volume containing Taq DNA
polymerase (1U; Finnzyme, Espoo, Finland), deoxynucleotide
triphosphates (0.2mM; Finnzyme, Espoo, Finland), reaction buffer
(5ml; Finnzyme, Espoo, Finland), the primers forward
(0.2pmolml
 1; Proligo, Boulder, CO, USA): 50-ACTGAATATAAA
CTTGTGGTAGTTGGACCT-30 and reverse (0.2pmolml
 1; Proligo,
Boulder, CO, USA): 50-TCAAAAGAATGGTCCTGCACCAG-30. The
forward primer creates the restriction site for BstNI, which is lost
when K-Ras is mutated at codon 12.
For amplification, a DNA thermocycler (MBS 0.2S, Hybaid,
Ashford, UK) was used. Cycling conditions of the first PCR were as
follows: initial denaturation (4min at 941C), followed by 40 cycles
of denaturation (30s at 941C), annealing (15s at 531C), and
elongation (30s at 721C). An elongation of 10min at 721C followed
the last cycle; at the end, samples were kept at 41C. Twenty
microlitres of the PCR reaction were then digested with BstNI for
4h at 601C in a total volume of 50ml. When codon 12 is wild-type,
the PCR product contains a restriction site for BstNI, and digestion
yields bands of 128 and 29bp. If there is a mutation in either of the
first two bases of codon 12, the mutant PCR fragment will not be
cut and will remain at its original size of 157bp. Digested products
were visualised by electrophoresis on a 3% agarose gels (contain-
ing 0.5mgml
 1 ethidium bromide). Positive (SW480 cell line) and
negative controls (Human Placental DNA) for the mutation and
controls for carryover DNA contamination were included in every
experiment. B-Raf V599E mutations were analysed first by
amplification using primers forward (0.2pmolml
 1; Proligo,
Boulder, CO, USA): 50-CTGTTTTCCTTTACTTACTACACCTCA
GATA-30 and reverse (0.2pmolml
 1; Proligo, Boulder, CO, USA):
50-CTCAATTCTTACCATCCACAAAATG-30. After 40 cycles of
amplification (annealing temperature 551C), amplified DNA was
subjected to TspRI (New England Biolabs, Beverly, MA, USA)
restriction digestion because this mutation abrogates a restriction
site present in the wild-type sequence. After incubation with the
enzyme at 651C overnight, the products were analysed on 3%
agarose gels. Special care was taken to directly load the samples at
high temperature (701C) and in the presence of formamide (0.2%)
to avoid reannealing of the restricted products (TspRI leaves a
nine-base 30 overhang). DNA containing the wild-type (Human
Placental DNA) or the mutated T1976 sequence (HT29 cell line)
was always included as controls.
P53 mutation
We used both SSCP and immunohistochemistry.
SSCP By SSCP we identified samples with altered p53 migratory
pattern, by gene mutation or polymorphism. Briefly, PCR
fragments were generated from 200ng of genomic DNA in a
50ml PCR reaction buffer. The primers (0.4pmolml
 1; Proligo,
Boulder, CO, USA) and the condition for PCR are described in the
Table 1 of Supplementary Appendix available on the BJC website.
DNA containing the wild-type p53 (Human Placental DNA) was
always included as controls. For SSCP analysis, PCR product was
mixed with an equal volume of loading buffer containing 100%
formamide (Sigma, Saint Louis, MO, USA), 0.05% xylene cyanol
(Sigma, Saint Louis, MO, USA), and 0.05% bromphenol blue
(Amersham Bioscience Corporation, Buckinghamshire, UK);
heated at 961C for 10min and put on ice before being loaded on
37.5% TBE polyacrylamide gels and electrophoresed for 1h at
100V and 4–5h at 300V. The gels were silver stained with
DNA Silver Staining Kit (Amersham Bioscience Corporation,
Buckinghamshire, UK) according to the manufacturer’s recom-
mendations.
Immunohistochemistry To analyse p53 expression, formalin-
fixed paraffin-embedded tissue sections (2mm) were used,
deparaffinised and exposed to an antigen retrieval system (1mM
EDTA, pH 8, and 981C for 30min) before being incubated with the
specific p53 antibody (1:1000, Ab-2, Calbiochem; Oncogene
Research Products, Cambridge, MA, USA). Endogenous per-
oxidase was blocked with 3% hydrogen peroxide for 20min at
room temperature. Primary mouse monoclonal antibody was
applied for 1h at room temperature. Reactive sites were identified
with secondary antibody (HRP rabbit/mouse, ChemMate DAKO
Envision, Carpinteria, CA, USA) for 30min at room temperature.
Immunoperoxidase staining, using diaminobenzidine as chromo-
gen, was carried out (DABþchromogen X-50, ChemMate,
DAKOCytomation, Carpinteria, CA, USA). The slides were
counterstained with hematoxylin (Harris Hematoxylin, DiaPath,
Microstain Division, Martinengo, BG, Italy). An abnormal SSCP
pattern coincidental with p53 nuclear immunoreactivity was taken
as indicative of cases with p53 mutation. Indeed, an altered SSCP
pattern may be merely related to gene polymorphism and as such
being not indicative of an abnormally mutated gene. On the other
hand, the mere immunocytochemical detection of p53 gene
product may also be due to an increased protein stabilisation
uncoupled from mutation (Cripps et al, 1994). Therefore, the less
expensive, quick and efficient way to detect p53 mutations is to
associate an abnormal SSCP pattern with the nuclear immuno-
cytochemical detection of the gene product.
RASSF1A, E- Cadherin and p16INK4A methylation
As previously reported (Roncalli et al, 2002), 1mg of genomic DNA
in a volume of 50ml was denatured by NaOH for 10min at 371C;
30mlo f1 0m M hydroquinone (Sigma, Saint Louis, MO, USA) and
520mlo f3 M sodium bisulphite (Sigma, Saint Louis, MO, USA) at
pH 5, both freshly prepared, were added and mixed, and samples
were incubated at 501C for 16h. Modified DNA was purified using
the Wizard DNA purification resin according to the manufac-
turer’s instruction (Promega, Milano, Italy) and eluted into 50ml
of water. Modification was completed by NaOH treatment (final
concentration 0.3 M) for 5min at room temperature, followed by
ethanol precipitation. DNA was resuspended in water and used
immediately or stored at  201C. Polymerase chain reaction was
performed separately with methylation-specific primers
(0.12pmolml
 1; Proligo, Boulder, CO, USA) and unmethylation
primers (0.12pmolml
 1; Proligo, Boulder, CO, USA) for each gene
(Supplementary Appendix, Table 1). Unmethylated (Human
Placental DNA) and methylated DNA (LoVo, COLO320 and HepG2
cell lines for RASSF1A, E-Cadherin and p16INK4A, respectively)
were used as MSP controls. Polymerase chain reaction products
were analysed on 2% agarose gels, stained with ethidium bromide
(0.5mgml
 1), and visualised under UV illumination. A sample was
classified as methylated whenever a band, corresponding to the
molecular weight of the methylated PCR product, had a thickness
and staining intensity equal or greater than that of the
unmethylated PCR product. Figure 1 of Supplementary Appendix
available on the BJC website illustrates an example of methylated
and unmethylated PCR products.
Statistical analyses
Data were described as number and percentage or means and s.d.,
whether appropriate. Differences in frequencies of variables were
tested using the w
2 test (Pearson or Fisher, if appropriate), and
differences in mean levels of variables were tested using the t-test.
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variables found to have a P-value p0.1 in the univariate evaluation
were considered to be candidates for a subsequent stepwise
multivariate logistic regression analysis. Data analysis was
performed using STATA9.
RESULTS
Genetic changes
The mutational status of K-Ras, B-Raf and p53 in 202 cases of CRC
is shown in Table 2a.
K-Ras Codon 12 K-Ras mutations were found in 54 cases (27%).
By univariate analysis, K-Ras mutations were significantly
associated with Mþ tumours (P¼0.016) and more frequent
detectable in the right side (P¼0.088). Multivariate analysis
confirmed the association between K-Ras mutations and Mþ
tumours (OR 2.37, 95% CI, 1.15–4.88, P¼0.019).
B-Raf Seven cases (3%) showed B-Raf mutation but none of these
had a coincidental mutation in the K-Ras gene nor a statistical
association with the other clinico-pathological variables.
p53 An altered SSCP pattern was identified in 91 (45%) out of
202 samples, whereas p53 nuclear immunoreactivity was detected
in 115 (57%) out of 202 cases. A coincidental abnormal SSCP
migratory pattern and p53 nuclear immunoreactivity was docu-
mented in 65 (32%) out of 202 cases.
No association was found in cases showing both genetic and
phenotypic p53 abnormalities with the clinico-pathological para-
meters under study.
Epigenetic changes
All cases showing PCR products for methylated DNA sequences
also exhibited unmethylated DNA sequences, which was related to
tumour heterogeneity or to the occurrence of intermingled non-
neoplastic cells. The epigenetic profile of RASSF1A, E-Cadherin
and p16INK4A in CRC is shown in Table 2b.
RASSF1A Out of 202 tumours, RASSF1A was methylated in 40
(20%) tumours, the majority occurring in Mþ tumours
(P¼0.021). No other association was found between RASSF1A
methylation and the clinico-pathological parameters under study.
E-Cadherin Out of 202 cases, E-Cadherin methylation was
detected in 88 (44%) cases. E-Cadherin methylation was more
frequently detectable in the right colon (P¼0.011) and in older
patients (P¼0.002). E-Cadherin methylation was also associated
with RASSF1A methylation (P¼0.047). All these variables retained
a statistical significance in multivariate analysis (right side: OR
0.59, 95% CI, 0.40–0.87, P¼0.007; older age: OR 1.039, 95% CI,
1.01–1.07, P¼0.004; RASSF1A methylation: OR 2.11, 95% CI,
1.01–4.41, P¼0.047).
p16INK4A Out of 202 cases, p16INK4A promoter methylation
was found in 67 (33%) cases. p16INK4A methylation was
significantly associated with Mþ tumours (Po0.001). p16INK4A
methylation was associated with B-Raf mutations (Po0.001),
RASSF1A (P¼0.004) and E-Cadherin (P¼0.040) methylation.
p16INK4A methylation was more frequently detectable in p53
mutated cases (P¼0.075). Multivariate analysis showed that gene
methylation was statistically associated with Mþ tumours (OR
3.48, 95% CI, 1.66–7.26, P¼0.001) and with RASSF1A methylation
(OR 2.29, 95% CI, 1.07–4.89, P¼0.032).
Coincidental genetic and epigenetic changes
Out of 202 CRCs, thirty-four (17%) were free from molecular
abnormalities and with no association with Mþ vs M  tumours.
Regardless the type of molecular abnormalities, 68 cases (34%)
showed one molecular alteration, 57 cases (28%) two molecular
alterations and 43 cases (21%) X3 molecular alterations. No
statistical association was seen between Mþ and M  CRCs
showing one or two gene alterations. Conversely, the frequency of
CRCs in the group showing three or more alterations was higher
in Mþ than in M  tumours (34/130¼26% vs 9/72¼12%;
P¼0.023). In the latter (X3 abnormalities) group, the most
frequent combination of genes was one genetic and two epigenetic
alterations, particularly K-Ras mutations (18/34¼53%), with gene
methylation equally affecting the three genes under study
(RASSF1A, E-Cadherin and p16INK4A). Coincidental methylation
Table 2a Genetic alterations: mutation frequencies for K-Ras, B-Raf and p53
All cases K-Ras B-Raf p53
No. No. (%) No. (%) No. (%)
All patients 202 54 (27%) 7 (3%) 65 (32%)
Age (years7s.d.) 66.05711.66 67.16711.56 NS 64.42713.50 NS 65.23712.17 NS
Sex
F 81 24 (30%) NS 2 (2%) NS 22 (27%) NS
M 121 30 (25%) 5 (4%) 43 (35%)
Tumour
M  72 12 (17%) P¼0.016 1 (1%) NS 26 (36%) NS
M+ 130 42 (32%) 6 (5%) 39 (23%)
Location
R 71 25 (35%) 5 (7%) 23 (32%)
L 78 15 (19%) P¼0.088 1 (1%) NS 23 (29%) NS
Re 53 14 (26%) 1 (2%) 19 (36%)
Grading
G1 14 5 (36%) — 4 (29%)
G2 145 38 (26%) NS 4 (3%) NS 48 (33%) NS
G3 43 11 (26%) 3 (7%) 13 (30%)
F¼female; L¼left side; M¼male; M+¼metastatic tumours; M ¼nonmetastatic tumours; NS¼not significant; R¼right side; Re¼rectum; s.d.¼standard deviation.
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Mþ CRCs (P¼0.042).
Multivariate analysis of variables associated with Mþ
tumours
Among the variables associated with Mþ cancers in univariate
analysis (K-Ras mutation, p16INK4A methylation, RASSF1A
methylation, younger age and grading), multivariate analysis
showed that only K-Ras mutations (OR 2.98, 95% CI, 1.37–6.46,
P¼0.006), p16INK4A methylation (OR 4.58, 95% CI, 2.14–9.76,
Po0.001) and younger age (OR 0.95, 95% CI, 0.92–0.98, Po0.001)
retained a statistically significant value.
DISCUSSION
Aim of this study was to characterise genetic and epigenetic
molecular alterations occurring in primary advanced Mþ and M 
CRCs.
The model of CRC relies upon the sequential accumulation of
genetic and epigenetic changes but, in our study, 17% of cases had
no abnormalities in the investigated genes (K-Ras, B-Raf, p53,
RASSF1A, E-Cadherin, p16INK4A). These data are in agreement
with previous studies examining different sets of genes. Smith et al
(2002) investigated K-Ras, p53 and APC in 106 cases and 10% CRC
were reported free of molecular abnormalities. Lee et al (2004)
examined promoter methylation of 12 different genes in 149 CRCs
and found that 9% were unmethylated. Chiang et al (2004) also
demonstrated that the three key mutations (APC, K-Ras and p53)
are rarely coincidental in 122 sporadic CRCs. All these findings
suggest that alterations in the genes mostly involved in colorectal
carcinogenesis are not always requested for tumour progression.
We found 27% K-Ras mutations in the whole series and a
statistical association with Mþ tumours (univariate analysis
P¼0.016; multivariate analysis P¼0.019), suggesting K-Ras
activation as an important determinant of extracolic tumour
spread. Gonzalez-Aguilera et al (2004) found increased K-Ras
mutations in tumours with advanced Duke’s stage (A 22%, B 27%,
C 38% and D 33%), particularly when grouping Mþ (46%) vs M 
tumours (26%). Aberrant activation of K-Ras has been implicated
in facilitating all aspects of a malignant phenotype, including
proliferation, invasion and metastases by Ras effectors such as
PIK3, Raf/MEK/ERK cascade and Rho GTPases. Recently, some
authors proposed that epithelial cells with activated Ras signalling
require the cooperation of other signalling pathway to became
metastogenic (Grunert et al, 2003) and the oncogenic Ras is
thought to cooperates with several other proto-oncogenes such as
p53 and p16INK4A (Serrano et al, 1996; Aguirre et al, 2003). This
cooperation between Ras and other genes is likely to occur in CRC
progression because, in our study, only 6% of tumours showed the
exclusive presence of K-Ras mutation. E-Cadherin promoter
methylation was prevalent in the right colon (univariate analysis
P¼0.011; multivariate analysis P¼0.007), so that coincidental
K-Ras mutations and E-Cadherin methylation frequently occurred
in proximal (27%) rather than left colon (5%) and rectum (8%)
(Po0.001). Whether E-Cadherin methylation and K-Ras mutation
cooperate in right side colonic carcinogenesis and progression
have to be confirmed in larger series. B-Raf was rarely found
mutated in our cases and never in conjunction with K-Ras.A s
previously noted (Rajagopalan et al, 2002; Yuen et al, 2002), K-Ras
and B-Raf mutations appear to be mutually exclusive, confirming
previous suggestions that they have similar biological targets in the
RAS-RAF-MEK-ERK-MAP kinase signalling pathway (Yuen et al,
2002). A small proportion of cases (10/202¼5%) showed both
K-Ras mutations and RASSF1A methylation; interestingly all these
cases were Mþ (P¼0.016). Whether alterations in both these
genes may be able to confer a more aggressive phenotype remains
to be established in larger series.
In our study, p53 abnormalities were not prevalent in Mþ
tumours suggesting a limited role of p53 in CRC metastatisation.
Different results were reported by Goh et al (1999) that used only
SSCP to detect p53 mutations.
Among tumour suppressor genes showing DNA methylation,
p16INK4A seems to play a major role in the metastogenic
phenotype of primary CRCs. Methylation was seen in 33% of the
whole series and it was, like K-Ras mutation, significantly
associated with a Mþ phenotype (univariate analysis P¼0.011;
multivariate analysis P¼0.001). A strong correlation between
staging and p16INK4A methylation was found also by Yi et al
(2001); loss of p16INK4A expression has been previously
associated with lymph-node metastases (Kim et al, 2005a) and
Table 2b Epigenetic alterations: promoter methylation frequencies for RASSF1A, E-Cadherin and p16INK4A
All cases RASSF1A E-CAD p16INK4A
No. No. (%) No. (%) No. (%)
All patients 202 40 (20%) 88 (44%) 67 (33%)
Age (years7s.d.) 66.05711.66 66.75712.52 NS 68.86710.63
a NS 67.25712.02 NS
Sex
F 81 18 (22%) NS 34 (42%) NS 27 (33%) NS
M 121 22 (18%) 54 (45%) 40 (33%)
Tumour
M  72 8 (11%) P¼0.021 34 (47%) NS 12 (17%) Po0.001
M+ 130 32 (25%) 54 (41%) 55(42%)
Location
R 71 14 (20%) 41 (58%) 24 (34%)
L 78 15 (19%) NS 29 (37%) P¼0.011 27 (35%) NS
Re 53 11 (21%) 18 (34%) 16 (30%)
Grading
G1 14 3 (21%) 7 (50%) 5 (36%)
G2 145 28 (19%) NS 65 (45%) NS 48 (33%) NS
G3 43 9 (21%) 16 (37%) 14 (33%)
F¼female; L¼left side; M¼male; M+¼metastatic tumours; M ¼nonmetastatic tumours; NS¼not significant; R¼right side; Re¼rectum; s.d.¼standard deviation.
aMethylated vs nonmethylated¼68.86710.63 vs 63.89711.99 (P¼0.002).
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results suggest that p16INK4A methylation might link to a
more malignant phenotype in CRC; interestingly Liang et al
(1999) recently reported an association between p16INK4A
methylation and shorter survival of CRC. Coincidental alterations
of K-Ras and p16INK4A were mainly found in Mþ tumours (2/67
M  tumours vs 17/139 Mþ tumours; P¼0.034), suggesting that
abnormalities in these pathways could cooperate for a more
aggressive phenotype, as previously supported by Serrano et al
(1997).
Another focus of this study was to examine the interactions
between genetic and epigenetic alterations in the induction of a
metastogenic phenotype. Regardless the type of molecular
abnormalities, tumours with three or more but not those with
less than three, were significantly more prevalent in the group of
Mþ tumours (P¼0.023). This means that the genes under study
can confer a more aggressive phenotype when molecular changes
deregulate at least three of them. This hypothesis is in keeping with
a stepwise model of progression of CRC. Given that a fraction of
M  CRCs (13%) already harbours three or more molecular
changes, we are currently analysing this cohort to ascertain
whether these cases will develop metachronous liver metastasis
at an increase rate as compared to M  CRCs with o3 molecular
changes. The group of Mþ tumours showing three or more
abnormal genes was characterised by a single genetic mutation
(usually K-Ras; 53%) and by two epigenetic alterations (equally
affecting p16INK4A, RASSF1A and E-Cadherin). Notably, Toyota
et al (2000) found K-Ras mutations significantly prevalent in CRCs
with the so called methylator phenotype (CIMP) compared with
CIMP negative cases. A stepwise increase in the number of
methylated genes was observed with lesion progression through
the stages of multistep colorectal carcinogenesis by Lee et al
(2004). Our study showed that coincidental methylation of the
three genes (RASSF1A, E-Cadherin and p16INK4A) was restricted
to Mþ tumours (P¼0.042). It is unclear why advanced and Mþ
CRCs showed a high degree of methylation: perhaps advanced
tumours inherited a major biological aggressiveness or were
simply more likely to become methylated. Notably, patients
showing three methylated genes were also of older age (73.83 vs
65.60 years; P¼0.017), in keeping with the suggestion put
forwards by Toyota and Issa (1999) that age-related methylation
might contribute to the sharp increase in cancer risk after the age
of 60 years.
Interestingly, in the present study, younger age was statistically
associated to Mþ tumours. This is likely due to internal selection
for surgical treatment, being the older age a limiting factor for
radical surgical resection (Leporrier et al, 2006).
In conclusion, analysis of a panel of genes provided to detect
some genetic and epigenetic molecular differences between Mþ
and M  primary CRCs. A set of genetic and epigenetic molecular
abnormalities is a feature of primary Mþ CRCs likely conferring
the ability for tumour extracolic spread and determining markers
for aggressive behaviour and potential therapeutic targets.
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